drugset / Trial / NCT04764006
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
NaSingle-groupOpen-labelTreatment
Summary
A phase II study to assess the efficacy and safety of Surufatinib combined with Sintilimab as a second-line treatment in patients with advanced MSS-Type CRC.
Timeline
- Start
- 2021-10-13
- Primary completion
- 2022-10-01
- Completion
- 2023-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Surufatinib | Small molecule | 250 mg | Oral |